Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
STANDARD-DOSE CISPLATIN WITH RHG-CSF ALLOWS SUFFICIENT HARVESTING OF PBSC FOR AUTOTRANSPLANTATION IN PATIENTS WITH OVARIAN-CANCER
Autore:
KURATA H; TAKAKUWA K; YOSHIYA N; KODAMA S; TANAKA K;
Indirizzi:
NIIGATA UNIV,SCH MED,DEPT OBSTET & GYNECOL,ASAHIMACHI DORI 1-757 NIIGATA 951 JAPAN
Titolo Testata:
International journal of gynecological cancer
fascicolo: 6, volume: 6, anno: 1996,
pagine: 491 - 495
SICI:
1048-891X(1996)6:6<491:SCWRAS>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; BLOOD PROGENITOR CELLS; HEMATOPOIETIC STEM-CELLS; AUTOLOGOUS BONE-MARROW; HUMAN CORD-BLOOD; AUTO-TRANSPLANTATION; BREAST-CANCER; GM-CSF; CHEMOTHERAPY; CYCLOPHOSPHAMIDE;
Keywords:
CISPLATIN; G-CSF; OVARIAN CANCER; PBSC;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
H. Kurata et al., "STANDARD-DOSE CISPLATIN WITH RHG-CSF ALLOWS SUFFICIENT HARVESTING OF PBSC FOR AUTOTRANSPLANTATION IN PATIENTS WITH OVARIAN-CANCER", International journal of gynecological cancer, 6(6), 1996, pp. 491-495

Abstract

We have investigated the feasibility of a program of autologous peripheral blood stem cell (PBSC) harvesting and transplantation in patients with ovarian cancer. From four patients, PBSC was collected during hematopoietic recovery following aplasia induced by standard dose cisplatin 70 mg m(-2) with etoposide 500 mg m(-2) or adriamycin 40 mg m(-2)and cyclophosphamide 500 mg m(-2) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) at a dose of 75 mu g day(-1) givenintracutaneously. In apheresed patients, we harvested an average of 2.31 x 10(5) kg(-1) colony-forming unit granulocyte/macrophage (range 0-5.22) per cycle. Low hematologic toxicity was observed during the hematopoietic reconstitution of the four patients subjected to PBSC support with G-CSF (5 mu g kg(-1) day(-1) given by continuous infusion) after high-dose chemotherapy (carboplatin 900 mg m(-2) and etoposide 900 mg m(-2)). The patients were not evaluable for a response because we performed consolidated high-dose chemotherapy. However, no evidence of recurrence has been observed 11.8 months (range 2-19) after high-dose chemotherapy. We can conclude that standard dose cisplatin in combination with etoposide or adriamycin and cyclophosphamide plus rhG-CSF allows sufficient harvesting of PBSC for autotransplantation in patients with ovarian cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 19:00:24